James Dahlman
Biography
James Dahlman is the McCamish Early Career Professor in the Department of Biomedical Engineering at Georgia Tech and Emory School of Medicine. His lab works at the interface of chemical engineering, genomics, and gene editing by applying big data approaches to nanomedicine. His lab is known for developing DNA barcoded nanoparticles to measure how hundreds of nanoparticles deliver mRNA and siRNA in multiple cell types from a single animal in vivo. The lab uses these approaches to deliver RNA outside the liver.
James was a co-founder and Board Chairman of Guide Therapeutics, which was acquired by Beam Therapeutics. His trainees have become investors, started companies, and work in some of the most cutting-edge organizations in RNA therapeutics. James received his Ph.D. in 2015 from the Harvard-MIT HST Program, where he studied with Robert Langer, and as a post-doc, studied CRISPR-Cas9 with Feng Zhang.
Research Interests
Professor Dahlman’s research centers on the development of novel gene delivery systems and nanotechnologies for therapeutic applications. His work involves designing nanoparticles to improve nucleic acid delivery efficiency and specificity, with a focus on understanding the interactions between engineered materials and biological systems. The research aims to advance nonviral gene therapies and develop tools for precise manipulation of cellular function in vivo.
